TW200700388A - Process for the preparation of opioid modulators - Google Patents

Process for the preparation of opioid modulators

Info

Publication number: TW200700388A
Authority: TW; Taiwan
Prior art keywords: preparation; opioid modulators; opioid; modulators; agonists
Prior art date: 2005-03-14

Application number

TW095108513A

Other languages

English (en)

Inventor

chao-zhong Cai

Wei He

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-14

Filing date

2006-03-14

Publication date

2007-01-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36646011&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200700388(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-03-14 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2007-01-01 Publication of TW200700388A publication Critical patent/TW200700388A/zh

Links

238000000034 method Methods 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title abstract 2
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
208000027520 Somatoform disease Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
208000027753 pain disease Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW095108513A 2005-03-14 2006-03-14 Process for the preparation of opioid modulators TW200700388A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US66178405P	2005-03-14	2005-03-14
US11/368,564 US7629488B2 (en)	2005-03-14	2006-03-06	Process for the preparation of opioid modulators

Publications (1)

Publication Number	Publication Date
TW200700388A true TW200700388A (en)	2007-01-01

Family

ID=36646011

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
TW101129655A TWI500595B (zh)	2005-03-14	2006-03-14	製備類鴉片調節劑之方法（一）
TW095108513A TW200700388A (en)	2005-03-14	2006-03-14	Process for the preparation of opioid modulators
TW095108512A TWI414518B (zh)	2005-03-14	2006-03-14	製備類鴉片調節劑之方法（一）

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
TW101129655A TWI500595B (zh)	2005-03-14	2006-03-14	製備類鴉片調節劑之方法（一）

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TW095108512A TWI414518B (zh)	2005-03-14	2006-03-14	製備類鴉片調節劑之方法（一）

Country Status (30)

Country	Link
US (4)	US7629488B2 (zh)
EP (2)	EP1863764A1 (zh)
JP (3)	JP5384933B2 (zh)
KR (2)	KR101280929B1 (zh)
CN (2)	CN101175726A (zh)
AR (2)	AR054745A1 (zh)
AU (2)	AU2006223482A1 (zh)
BR (2)	BRPI0607793A2 (zh)
CA (2)	CA2601481C (zh)
CR (1)	CR9438A (zh)
CY (1)	CY1116104T1 (zh)
DK (1)	DK1858850T3 (zh)
EA (2)	EA014366B1 (zh)
ES (1)	ES2535048T3 (zh)
HR (1)	HRP20150417T1 (zh)
HU (1)	HUE024912T2 (zh)
IL (3)	IL185972A (zh)
ME (1)	ME02110B (zh)
MX (2)	MX2007011412A (zh)
MY (1)	MY145333A (zh)
NI (1)	NI200700237A (zh)
NO (2)	NO340604B1 (zh)
NZ (1)	NZ590570A (zh)
PL (1)	PL1858850T3 (zh)
PT (1)	PT1858850E (zh)
RS (1)	RS53873B1 (zh)
SI (1)	SI1858850T1 (zh)
TW (3)	TWI500595B (zh)
WO (2)	WO2006099060A2 (zh)
ZA (2)	ZA200708809B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7041681B2 (en) *	2002-04-29	2006-05-09	Janssen Pharmaceutica N.V.	Compounds as opioid receptor modulators
TWI361069B (en) *	2004-03-15	2012-04-01	Janssen Pharmaceutica Nv	Novel compounds as opioid receptor modulators
MX2007011412A (es) *	2005-03-14	2008-02-22	Johnson & Johnson	Procedimiento para la preparacion de moduladores de opioide.
CN101730685A (zh)	2007-07-09	2010-06-09	詹森药业有限公司	5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法
TWI468375B (zh) *	2008-10-27	2015-01-11	Janssen Pharmaceutica Nv	製備經保護之ｌ－丙胺酸衍生物之方法
IS2977B (is)	2015-02-23	2017-07-15	Actavis Group Ptc Ehf.	Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017043626A1 (ja) *	2015-09-11	2017-03-16	株式会社カネカ	光学活性４－カルバモイル－２，６－ジメチルフェニルアラニン誘導体の製造法
CN105777584B (zh) *	2016-03-28	2018-01-02	成都伊诺达博医药科技有限公司	丙氨酸衍生物的制备方法
CN105693554B (zh) *	2016-04-06	2017-08-08	成都伊诺达博医药科技有限公司	丙氨酸衍生物的制备方法
EP3474847B1 (en) *	2016-06-23	2022-09-07	Sun Pharmaceutical Industries Limited	Processes for the preparation of eluxadoline
WO2018047131A1 (en) *	2016-09-09	2018-03-15	Sun Pharmaceutical Industries Limited	Amorphous eluxadoline
EP3515434A4 (en)	2016-09-20	2020-02-26	Sun Pharmaceutical Industries Limited	METHOD FOR PRODUCING ELUXADOLIN
CN106866463B (zh) *	2017-01-24	2018-08-28	富乐马鸿凯（大连）医药有限公司	艾沙度林中间体的制备方法
US10738013B2 (en)	2017-01-27	2020-08-11	Quimica Sintetica, S.A.	Eluxadoline crystalline forms and processes for their preparation
WO2018138272A1 (en)	2017-01-27	2018-08-02	Quimica Sintetica, S. A.	Eluxadoline crystalline form and process for the preparation thereof
CN111377832A (zh) *	2018-12-27	2020-07-07	江苏联昇化学有限公司	一种伊卢多啉中间体制备的新方法
WO2021201036A1 (ja)	2020-03-31	2021-10-07	田辺三菱製薬株式会社	ヒドロキシピロリジン誘導体およびその医薬用途
CN114163348A (zh) *	2020-11-27	2022-03-11	成都泰蓉生物科技有限公司	一种氨酰基取代的l-苯丙氨酸的合成方法
CN114507252B (zh) *	2022-02-21	2023-10-27	广西大学	新型芳基硅烷化合物的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5430129A (en) *	1977-08-09	1979-03-06	Mitsubishi Gas Chem Co Inc	Preparation of toluic acid amide
JPS5528959A (en) *	1978-08-22	1980-02-29	Sumitomo Chem Co Ltd	Production of amide derivative
FR2584401B1 (fr) *	1985-07-04	1987-11-20	Ile De France	Nouveau benzamide, son procede de preparation et son application dans le domaine therapeutique
JP2727243B2 (ja) *	1988-12-27	1998-03-11	日本化薬株式会社	２−アシルアミノ桂皮酸誘導体の製造法
US5684175A (en) *	1993-02-05	1997-11-04	Napro Biotherapeutics, Inc.	C-2' hydroxyl-benzyl protected, N-carbamate protected (2R, 3S)- 3-phenylisoserine and production process therefor
JP3493206B2 (ja) *	1993-03-19	2004-02-03	ダイセル化学工業株式会社	光学活性β−アミノ酸類の製法
JP3486922B2 (ja) *	1993-08-23	2004-01-13	住友化学工業株式会社	酸アミドの製造法
EP0805816B1 (en) *	1995-01-27	2004-07-28	Novo Nordisk A/S	Compounds with growth hormone releasing properties
JPH09295939A (ja) *	1995-09-26	1997-11-18	Takeda Chem Ind Ltd	リン酸アミド誘導体、その製造法および用途
GEP20043179B (en) *	1998-03-11	2004-02-25	Searle & Co	Halogenated Amidino Amino Acid Derivatives Useful as Nitric Oxide Synthase Inhibitors
EP1055665B1 (en) *	1999-05-28	2003-10-22	Pfizer Products Inc.	3-(3-Hydroxyphenyl)-3-amino-propionamide derivatives
CA2422617C (en) *	2000-10-30	2011-07-12	Janssen Pharmaceutica N.V.	Tripeptidyl peptidase inhibitors
US7041681B2 (en) *	2002-04-29	2006-05-09	Janssen Pharmaceutica N.V.	Compounds as opioid receptor modulators
TWI361069B (en) *	2004-03-15	2012-04-01	Janssen Pharmaceutica Nv	Novel compounds as opioid receptor modulators
MX2007011412A (es) *	2005-03-14	2008-02-22	Johnson & Johnson	Procedimiento para la preparacion de moduladores de opioide.

2006
- 2006-03-06 MX MX2007011412A patent/MX2007011412A/es active IP Right Grant
- 2006-03-06 JP JP2008501919A patent/JP5384933B2/ja not_active Expired - Fee Related
- 2006-03-06 CA CA2601481A patent/CA2601481C/en active Active
- 2006-03-06 KR KR1020077022664A patent/KR101280929B1/ko active IP Right Grant
- 2006-03-06 EP EP06737413A patent/EP1863764A1/en not_active Withdrawn
- 2006-03-06 EA EA200701979A patent/EA014366B1/ru not_active IP Right Cessation
- 2006-03-06 DK DK06737611.1T patent/DK1858850T3/en active
- 2006-03-06 ES ES06737611.1T patent/ES2535048T3/es active Active
- 2006-03-06 AU AU2006223482A patent/AU2006223482A1/en not_active Abandoned
- 2006-03-06 US US11/368,564 patent/US7629488B2/en active Active
- 2006-03-06 MX MX2007011409A patent/MX2007011409A/es unknown
- 2006-03-06 SI SI200631907T patent/SI1858850T1/sl unknown
- 2006-03-06 BR BRPI0607793-5A patent/BRPI0607793A2/pt not_active Application Discontinuation
- 2006-03-06 CN CNA2006800166320A patent/CN101175726A/zh active Pending
- 2006-03-06 HU HUE06737611A patent/HUE024912T2/en unknown
- 2006-03-06 KR KR1020077023282A patent/KR20070112255A/ko not_active Application Discontinuation
- 2006-03-06 BR BRPI0607792-7A patent/BRPI0607792A2/pt not_active IP Right Cessation
- 2006-03-06 US US11/368,588 patent/US20060211861A1/en not_active Abandoned
- 2006-03-06 RS RS20150121A patent/RS53873B1/en unknown
- 2006-03-06 PT PT67376111T patent/PT1858850E/pt unknown
- 2006-03-06 PL PL06737611T patent/PL1858850T3/pl unknown
- 2006-03-06 EP EP06737611.1A patent/EP1858850B1/en active Active
- 2006-03-06 ME MEP-2015-31A patent/ME02110B/me unknown
- 2006-03-06 CN CN2006800163712A patent/CN101175725B/zh not_active Expired - Fee Related
- 2006-03-06 NZ NZ590570A patent/NZ590570A/en not_active IP Right Cessation
- 2006-03-06 JP JP2008501912A patent/JP2008533141A/ja not_active Withdrawn
- 2006-03-06 EA EA200701978A patent/EA015512B1/ru unknown
- 2006-03-06 WO PCT/US2006/008450 patent/WO2006099060A2/en active Application Filing
- 2006-03-06 CA CA002601674A patent/CA2601674A1/en not_active Abandoned
- 2006-03-06 AU AU2006223394A patent/AU2006223394B2/en not_active Ceased
- 2006-03-06 WO PCT/US2006/008240 patent/WO2006098982A1/en active Application Filing
- 2006-03-14 TW TW101129655A patent/TWI500595B/zh not_active IP Right Cessation
- 2006-03-14 MY MYPI20061110A patent/MY145333A/en unknown
- 2006-03-14 AR ARP060100973A patent/AR054745A1/es active IP Right Grant
- 2006-03-14 TW TW095108513A patent/TW200700388A/zh unknown
- 2006-03-14 AR ARP060100974A patent/AR053170A1/es not_active Application Discontinuation
- 2006-03-14 TW TW095108512A patent/TWI414518B/zh active
2007
- 2007-09-13 NI NI200700237A patent/NI200700237A/es unknown
- 2007-09-16 IL IL185972A patent/IL185972A/en active IP Right Grant
- 2007-09-16 IL IL185974A patent/IL185974A0/en unknown
- 2007-10-12 CR CR9438A patent/CR9438A/es not_active Application Discontinuation
- 2007-10-12 ZA ZA200708809A patent/ZA200708809B/xx unknown
- 2007-10-12 ZA ZA200708810A patent/ZA200708810B/xx unknown
- 2007-10-15 NO NO20075269A patent/NO340604B1/no not_active IP Right Cessation
- 2007-10-15 NO NO20075268A patent/NO20075268L/no not_active Application Discontinuation
2009
- 2009-10-16 US US12/580,641 patent/US20100036132A1/en not_active Abandoned
- 2009-11-25 US US12/625,973 patent/US20100152460A1/en not_active Abandoned
2010
- 2010-11-18 IL IL209402A patent/IL209402A/en active IP Right Grant
2013
- 2013-07-16 JP JP2013147688A patent/JP5802242B2/ja not_active Expired - Fee Related
2015
- 2015-02-19 CY CY20151100172T patent/CY1116104T1/el unknown
- 2015-04-14 HR HRP20150417TT patent/HRP20150417T1/hr unknown

Also Published As

Publication number	Publication date
PL1858850T3 (pl)	2015-06-30
IL209402A0 (en)	2011-01-31
ZA200708810B (en)	2009-01-28
JP2013234192A (ja)	2013-11-21
WO2006099060A3 (en)	2006-11-02
CY1116104T1 (el)	2017-02-08
US20100036132A1 (en)	2010-02-11
SI1858850T1 (sl)	2015-04-30
CN101175725A (zh)	2008-05-07
CN101175726A (zh)	2008-05-07
KR101280929B1 (ko)	2013-07-01
NO340604B1 (no)	2017-05-15
EA015512B1 (ru)	2011-08-30
CA2601481C (en)	2013-11-12
JP5802242B2 (ja)	2015-10-28
JP2008533141A (ja)	2008-08-21
KR20070116067A (ko)	2007-12-06
ME02110B (me)	2015-10-20
ZA200708809B (en)	2009-03-25
US20060211863A1 (en)	2006-09-21
EP1863764A1 (en)	2007-12-12
MX2007011412A (es)	2008-02-22
CA2601481A1 (en)	2006-09-21
AU2006223394A1 (en)	2006-09-21
ES2535048T3 (es)	2015-05-04
PT1858850E (pt)	2015-02-24
AR054745A1 (es)	2007-07-11
US20060211861A1 (en)	2006-09-21
TW201302676A (zh)	2013-01-16
EP1858850A2 (en)	2007-11-28
NZ590570A (en)	2012-06-29
CR9438A (es)	2008-09-09
US7629488B2 (en)	2009-12-08
MY145333A (en)	2012-01-31
MX2007011409A (es)	2008-02-22
CA2601674A1 (en)	2006-09-21
WO2006098982A1 (en)	2006-09-21
TW200716548A (en)	2007-05-01
TWI414518B (zh)	2013-11-11
KR20070112255A (ko)	2007-11-22
AU2006223482A1 (en)	2006-09-21
DK1858850T3 (en)	2015-02-09
NI200700237A (es)	2008-06-25
IL209402A (en)	2015-06-30
TWI500595B (zh)	2015-09-21
NO20075268L (no)	2007-12-10
JP2008533143A (ja)	2008-08-21
RS53873B1 (en)	2015-08-31
BRPI0607793A2 (pt)	2009-06-13
JP5384933B2 (ja)	2014-01-08
HUE024912T2 (en)	2016-02-29
EA200701979A1 (ru)	2008-04-28
IL185972A0 (en)	2008-01-06
EP1858850B1 (en)	2015-01-21
NO20075269L (no)	2007-12-10
EA014366B1 (ru)	2010-10-29
IL185974A0 (en)	2008-01-06
AR053170A1 (es)	2007-04-25
US20100152460A1 (en)	2010-06-17
CN101175725B (zh)	2011-02-02
EA200701978A1 (ru)	2008-04-28
IL185972A (en)	2013-07-31
HRP20150417T1 (en)	2015-09-25
WO2006099060A2 (en)	2006-09-21
AU2006223394B2 (en)	2012-10-18
BRPI0607792A2 (pt)	2009-06-13

Publication	Publication Date	Title
MY145333A (en)	2012-01-31	Process for the preparation of opioid modulators
MY146972A (en)	2012-10-15	Novel compounds as opioid receptor modulators.
MY146662A (en)	2012-09-14	Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
TW200800976A (en)	2008-01-01	New compounds for the treatment of neurological, psychiatric or pain disorders
TW200531689A (en)	2005-10-01	Therapeutic agents
TW200612905A (en)	2006-05-01	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en)	2013-01-31	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TN2012000231A1 (en)	2013-12-12	Quinoline amide m1 receptor positive allosteric modulators
UA101493C2 (ru)	2013-04-10	Производные азетидина и циклобутана как ингибиторы jak
MY161834A (en)	2017-05-15	Substituted diazepan compounds as orexin receptor antagonists
TW200635903A (en)	2006-10-16	Therapeutic agents
MY161991A (en)	2017-05-31	Proteasome inhibitors
MY179527A (en)	2020-11-10	Catecholamine derivatives useful for the treatment of parkinson's disease
TW200716134A (en)	2007-05-01	Tricyclic opioid modulators
TW200633986A (en)	2006-10-01	Therapeutic agents
MX2009003981A (es)	2009-04-27	Agentes moduladores del receptor de calcio.
MEP1008A (xx)	2010-02-10	3-aminociklopentankarboksamidi kao modulatori receptora hemokina
JO2645B1 (en)	2012-06-17	Vehicles
MX2010010597A (es)	2010-10-25	Procesos para la preparacion de derivados de dioxina benzofusionados.
TW200734324A (en)	2007-09-16	Therapeutic agents
TNSN06260A1 (en)	2007-12-03	Process for the preparation of tryptase inhibitors
GB0519760D0 (en)	2005-11-09	Novel compounds
GB0407025D0 (en)	2004-04-28	Novel compounds
WO2008130319A3 (en)	2008-12-18	Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain
WO2007010222A3 (en)	2008-02-21	Therapeutic agents